drugset / Trial / NCT02672917
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
Timeline
- Start
- 2016-01
- Primary completion
- 2024-08-07
- Completion
- 2025-01-14
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVT-5873 | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |